Head-to-head · free
UnitedHealth Group vs Xenon Pharmaceuticals Inc.
UNH vs XENE — return on capital, cash generation, margins and balance sheet side by side.
UNH
4 / 5
measures where UNH leads
XENE
1 / 5
measures where XENE leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | UNH · FY2025 | XENE · FY2025 |
|---|---|---|
| Revenue | $447.6B | — |
| Net income | $12.1B | (345.9M) |
| Revenue growth (yearly, multi-year) | 11.7% | — |
| Free cash flow | $16.1B | (279.9M) |
| Free cash flow margin | 3.6% | — |
| Net cash / (debt) | (54.0B) | — |
| ROIC | 9.2% | — |
| Return on equity | 12.9% | -51.8% |
| Gross margin | 18.5% | — |
| Operating margin | 4.2% | -4974.3% |
| Net debt / EBITDA | 2.32x | 0.54x |
Figures are as reported by each company; latest fiscal year shown.
Where UnitedHealth Group's cash went (FY2025)
- Capital spending
- $3.6B
- Buybacks
- $5.5B
- Dividends
- $7.9B
- Acquisitions
- $4.5B
- Net debt issued / (repaid)
- $726.0M
Where Xenon Pharmaceuticals Inc.'s cash went (FY2025)
- Capital spending
- $799000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free